PURPOSE: This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC). PATIENTS AND METHODS: Patients were initially administered two treatments of Ad-p53 to a single involved lobe, beginning at 2 x 10(9) viral particles (vp) per dose and escalated to a maximum of 2 x 10(12) vp. If a clinical benefit was seen and the treatment was well tolerated, additional doses could be administered to additional lobes. RESULTS: Twenty-five patients were treated at doses between 2 x 10(9) and 2 x 10(12) vp. At 2 x 10(12) vp, one patient experienced grade 4 pulmonary toxicity, and one patient died 25 days after his second cycle; therefore, a cohort of 10 patients was treated at the recommended phase II dose of 5 x 10(11) vp, with no grade 4 toxicity observed. The most frequent toxicities included low-grade fever, hypoxia, and dyspnea. Of the 23 assessable patients, 16 had stable disease as their best response. Subjective improvement in breathing was noted in eight patients. Limited distribution of vector was observed, with transient detection in patient sputum for 1 to 2 days after administration. CONCLUSION: Ad-p53 can be administered safely by BAL at 5 x 10(11) vp with repeated dosing. Stabilization of disease and symptomatic improvement may warrant further studies of Ad-p53 or other adenoviruses administered by BAL in patients with BAC.
PURPOSE: This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC). PATIENTS AND METHODS: Patients were initially administered two treatments of Ad-p53 to a single involved lobe, beginning at 2 x 10(9) viral particles (vp) per dose and escalated to a maximum of 2 x 10(12) vp. If a clinical benefit was seen and the treatment was well tolerated, additional doses could be administered to additional lobes. RESULTS: Twenty-five patients were treated at doses between 2 x 10(9) and 2 x 10(12) vp. At 2 x 10(12) vp, one patient experienced grade 4 pulmonary toxicity, and one patient died 25 days after his second cycle; therefore, a cohort of 10 patients was treated at the recommended phase II dose of 5 x 10(11) vp, with no grade 4 toxicity observed. The most frequent toxicities included low-grade fever, hypoxia, and dyspnea. Of the 23 assessable patients, 16 had stable disease as their best response. Subjective improvement in breathing was noted in eight patients. Limited distribution of vector was observed, with transient detection in patient sputum for 1 to 2 days after administration. CONCLUSION: Ad-p53 can be administered safely by BAL at 5 x 10(11) vp with repeated dosing. Stabilization of disease and symptomatic improvement may warrant further studies of Ad-p53 or other adenoviruses administered by BAL in patients with BAC.
Authors: M Schuler; R Herrmann; J L De Greve; A K Stewart; U Gatzemeier; D J Stewart; L Laufman; R Gralla; J Kuball; R Buhl; C P Heussel; F Kommoss; A P Perruchoud; F A Shepherd; M A Fritz; J A Horowitz; C Huber; C Rochlitz Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Stephen G Swisher; Jack A Roth; Ritsuko Komaki; Jian Gu; J Jack Lee; Marshall Hicks; Jae Y Ro; Waun K Hong; James A Merritt; Kamaran Ahrar; N Edward Atkinson; Arlene M Correa; Marcelo Dolormente; Linda Dreiling; Adel K El-Naggar; Frank Fossella; Rhodette Francisco; Bonnie Glisson; Susan Grammer; Roy Herbst; Armando Huaringa; Bonnie Kemp; Fadlo R Khuri; Jonathan M Kurie; Zhongxio Liao; Timothy J McDonnell; Rudolfo Morice; Frank Morello; Reginald Munden; Vassiliki Papadimitrakopoulou; Katherine M W Pisters; Joe B Putnam; Arcenio J Sarabia; Thomas Shelton; Craig Stevens; Daniel M Shin; William R Smythe; Ara A Vaporciyan; Garrett L Walsh; Min Yin Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Anil Vachani; Edmund Moon; Elliot Wakeam; Andrew R Haas; Daniel H Sterman; Steven M Albelda Journal: Clin Chest Med Date: 2011-10-07 Impact factor: 2.878
Authors: Carrie Y Peterson; Ashkaun Shaterian; Alexandra K Borboa; Ana M Gonzalez; Bruce M Potenza; Raul Coimbra; Brian P Eliceiri; Andrew Baird Journal: Biomaterials Date: 2009-09-24 Impact factor: 12.479
Authors: Daniel H Sterman; Adri Recio; Andrew R Haas; Anil Vachani; Sharyn I Katz; Colin T Gillespie; Guanjun Cheng; Jing Sun; Edmund Moon; Luana Pereira; Xinzhong Wang; Daniel F Heitjan; Leslie Litzky; Carl H June; Robert H Vonderheide; Richard G Carroll; Steven M Albelda Journal: Mol Ther Date: 2010-01-12 Impact factor: 11.454